{"id":"cellgram-ed","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL3702598","moleculeType":"Small molecule","molecularWeight":"324.38"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the CD47/SIRPα interaction, Cellgram-ED aims to restore the ability of the immune system to recognize and eliminate cancer cells. This mechanism is thought to be particularly effective in treating various types of cancer.","oneSentence":"Cellgram-ED is a small molecule that targets the CD47/SIRPα axis to modulate the immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:50:29.274Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic solid tumors"},{"name":"Relapsed or refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT07431008","phase":"","title":"Safety Follow-up Study of Cellgram-ED in Post-Radical Prostatectomy Erectile Dysfunction","status":"RECRUITING","sponsor":"Pharmicell Co., Ltd.","startDate":"2024-12-26","conditions":"Erectile Dysfunction","enrollment":32},{"nctId":"NCT04594850","phase":"PHASE2","title":"Clinical Trial to Evaluate Efficacy and Safety of of Autologous Mesenchymal Stem Cells (MSC) Injected Intracavernously","status":"COMPLETED","sponsor":"Pharmicell Co., Ltd.","startDate":"2020-10-19","conditions":"Erectile Dysfunction","enrollment":54},{"nctId":"NCT02344849","phase":"PHASE1","title":"Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Erectile Dysfunction","status":"COMPLETED","sponsor":"Pharmicell Co., Ltd.","startDate":"2015-07","conditions":"Erectile Dysfunction","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Autologous bone marrow derived mesenchymal stem cell"],"phase":"phase_2","status":"active","brandName":"Cellgram-ED","genericName":"Cellgram-ED","companyName":"Pharmicell Co., Ltd.","companyId":"pharmicell-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Cellgram-ED is a small molecule that targets the CD47/SIRPα axis to modulate the immune response. Used for Metastatic solid tumors, Relapsed or refractory multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}